7 news items
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX
10 Jun 24
Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The stock options were granted as inducements material
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
CRNX
3 Jun 24
-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)
CRNX
3 Jun 24
results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
CRNX
30 May 24
in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
CRNX
22 May 24
in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward
ngosm67uyx
CRNX
10 May 24
Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The stock options were granted as inducements material
9jkpauggp0hlw0eu5i45
CRNX
11 Apr 24
Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The stock options were granted as inducements material
- Prev
- 1
- Next